U-M joins low-risk TAVR study
Procedures that rely on tiny tubes guided to the heart have transformed the way doctors treat severely ill patients who are too frail for surgery.
Now this surgery alternative is being investigated in a broader patient population, allowing 1,200 patients from across the country who are at low surgical risk to be considered for transcatheter aortic valve replacement (TAVR).
“The trial is designed to assess the safety and performance of a new approach to aortic valve replacement,” says G. Michael Deeb, M.D., the Herbert Sloan Collegiate Professor of Surgery and principal investigator for the trial at U-M.
The study is an expanded trial for the CoreValve Evolut R System, a next-generation device that’s designed to provide physicians the option to recapture the valve and reposition it during the procedure.
Once in place, the device expands and takes over the diseased valve’s function to enable oxygen-rich blood to flow efficiently out of the heart.
Cardiac teams at U-M have performed more than 700 TAVR procedures, making the heart center tops in the nation for investigational and real-world TAVR experience.
For questions about this study, contact Katie Wopinsky at 888-286-4420, or email firstname.lastname@example.org.